A Single-Arm, Exploratory, Self-Controlled Clinical Study of Hetrombopag for Secondary Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
Latest Information Update: 03 Dec 2025
At a glance
- Drugs Hetrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
Most Recent Events
- 03 Dec 2025 New trial record